NCT00763607

Brief Summary

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
454

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2007

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

September 30, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 1, 2008

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

September 10, 2022

Status Verified

September 1, 2022

Enrollment Period

2.1 years

First QC Date

September 30, 2008

Last Update Submit

September 8, 2022

Conditions

Non Small Cell Lung Cancer

Keywords

non small cell lung cancer patients

Outcome Measures

Primary Outcomes (1)

  • Association of different biomarkers with survival

    At the end of enrollment

Secondary Outcomes (1)

  • Association of a specific biomarker with patient's characteristics

    At the end of enrollment

Study Arms (1)

1

Radically resected Non small cell lung cancer patients in stage I-III

Genetic: Protein expression by immunohistochemistry and immunofluorescence

Interventions

Protein expression by immunohistochemistry and immunofluorescenceGENETIC

Protein expression by immunohistochemistry and immunofluorescence

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Radically resected non small cell lung cancer patients

You may qualify if:

  • Radically resected non small cell lung cancer patients with tumor tissue available

You may not qualify if:

  • Tumor tissue not available
  • Clinical data not available

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituto Clinco Humanitas

Rozzano, Milan, 20089, Italy

Location

Biospecimen

Retention: SAMPLES WITH DNA

Paraffine embedded tumor sections

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Fluorescent Antibody Technique

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

ImmunohistochemistryHistocytochemistryCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHistological TechniquesInvestigative TechniquesImmunologic Techniques

Study Officials

  • Armando Santoro, MD

    Istituto Clinico Humanitas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 30, 2008

First Posted

October 1, 2008

Study Start

November 1, 2007

Primary Completion

December 1, 2009

Study Completion

December 1, 2009

Last Updated

September 10, 2022

Record last verified: 2022-09

Locations

IT(1)